Stronger demand for infection control products has helped Tristel raise full-year pre-tax profits. The group boosted its final dividend and plans further expansion in Asia.
The contamination control group has identified fast-growing markets in the Middle East and Asia that offer “enormous opportunities”.
The purchase of intellectual and manufacturing rights products from Medichem International has strengthened the group’s presence globally, Tristel said.
Tristelsaid full-year revenue rose by 14 per cent from £5.9m to £6.8m, and pre-tax profit by 5.6 per cent from £1.22m to £1.29m.
Paul Swinney, chief executive said: “We have had another good year, achieving our fourth consecutive year of pre-tax profit growth since our flotation in 2005. Our business continues to grow both at home and in overseas markets and we look to the future with confidence.”
Earnings per share fell from 4.17p to 3.42p.
The board recommended a 9.7 per cent increase in the final dividend to 1.7p per share.
Shares in the group rose by 1.94 per cent to 51.48p.